相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration A Mixed-Methods Systematic Review
Mali Okada et al.
OPHTHALMOLOGY (2021)
Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure
Jean-Francois Korobelnik et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2021)
Delayed follow-up of medical retina patients due to COVID-19: impact on disease activity and visual acuity
Lydia G. Stone et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2021)
EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION The ARIES Study: A Randomized Clinical Trial
Paul Mitchell et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2021)
Real-World Effectiveness, Treatment Pattern, and Safety of Ranibizumab in Korean Patients with Neovascular Age-Related Macular Degeneration: Subgroup Analyses from the LUMINOUS Study
Min Sagong et al.
CLINICAL OPHTHALMOLOGY (2021)
PHARMACOKINETIC STUDY OF INTRAVITREAL AFLIBERCEPT IN HUMANS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Diana V. Do et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2020)
Macular Atrophy in Neovascular Age-Related Macular Degeneration A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study)
Mark C. Gillies et al.
OPHTHALMOLOGY (2020)
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52-and 96-Week Findings from ALTAIR A Randomized Controlled Trial
Masahito Ohji et al.
ADVANCES IN THERAPY (2020)
Recommendations by a UK expert panel on an aflibercept treat-and-extend pathway for the treatment of neovascular age-related macular degeneration
Adam H. Ross et al.
EYE (2020)
Off-label use of bevacizumab for wet age-related macular degeneration in Europe
Tomas Bro et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2020)
POSTTREATMENT POLYP REGRESSION AND RISK OF MASSIVE SUBMACULAR HEMORRHAGE IN EYES WITH POLYPOIDAL CHOROIDAL VASCULOPATHY
Joon Hee Cho et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2020)
SUSPENDING TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CASES OF FUTILITY
David T. Wong et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2020)
Bimonthly, treat-and-extend and as-needed ranibizumab in naive neovascular age-related macular degeneration patients: 12-month outcomes of a randomized study
Maria Isabel Lopez Galvez et al.
ACTA OPHTHALMOLOGICA (2020)
Efficacy and Treatment Burden of Intravitreal Aflibercept Versus Intravitreal Ranibizumab Treat-and-Extend Regimens at 2 Years: Network Meta-Analysis Incorporating Individual Patient Data Meta-Regression and Matching-Adjusted Indirect Comparison
Masahito Ohji et al.
ADVANCES IN THERAPY (2020)
Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease A Randomized Clinical Trial
Peter J. Kertes et al.
JAMA OPHTHALMOLOGY (2020)
Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies
Anna A. Plyukhova et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy The EVEREST II Randomized Clinical Trial
Tock H. Lim et al.
JAMA OPHTHALMOLOGY (2020)
Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen
Kimberly L. Spooner et al.
OPHTHALMOLOGY (2020)
Comparison of one-year results of photodynamic therapy combined with ranibizumab or aflibercept for treating polypoidal choroidal vasculopathy
Arisa Ito et al.
PLOS ONE (2020)
Two-Year Outcomes of Treat-and-Extend Intravitreal Aflibercept for Exudative Age-Related Macular Degeneration A Prospective Study
Ichiro Maruko et al.
OPHTHALMOLOGY RETINA (2020)
Impact of COVID-19 on Ophthalmology and Future Practice of Medicine
Kelvin H. Wan et al.
ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY (2020)
One-Year Results of a Treat-and-Extend Regimen of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy
Tomoko Tamachi et al.
OPHTHALMOLOGY AND THERAPY (2020)
Latest Developments in Polypoidal Choroidal Vasculopathy: Epidemiology, Etiology, Diagnosis, and Treatment
Voraporn Chaikitmongkol et al.
ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY (2020)
Genetic Association of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
Li Jia Chen
ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY (2020)
Comparative efficacy and safety of anti-vascular endothelial growth factor regimens for neovascular age-related macular degeneration: systematic review and Bayesian network meta-analysis
Lu Ye et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2020)
Real-World Treatment Outcomes of Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Asians
Beau J. Fenner et al.
OPHTHALMOLOGY RETINA (2020)
Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials
Glenn J. Jaffe et al.
OPHTHALMOLOGY (2019)
A real-world study of effectiveness of intravitreal bevacizumab and ranibizumab injection for treating retinal diseases in Thailand
Suthasinee Kumluang et al.
BMC OPHTHALMOLOGY (2019)
Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration A Randomized Clinical Trial
Mark C. Gillies et al.
JAMA OPHTHALMOLOGY (2019)
Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration
Alaa Din Abdin et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2019)
Treat and extend versus pro re nata regimens of ranibizumab and aflibercept in neovascular age-related macular degeneration: a comparative study
Michele Augsburger et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2019)
Priority options of anti-vascular endothelial growth factor agents in wet age-related macular degeneration under the National Health Insurance Program
Yu-Bai Chou et al.
JOURNAL OF THE CHINESE MEDICAL ASSOCIATION (2019)
Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat-and-extend compared with pro re nata in eyes with neovascular age-related macular degeneration
Sandra Aurell et al.
ACTA OPHTHALMOLOGICA (2019)
Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen FLUID Study 24-Month Results
Robyn H. Guymer et al.
OPHTHALMOLOGY (2019)
Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-Related Macular Disease
Peter J. Kertes et al.
OPHTHALMOLOGY (2019)
Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: Two-Year Results of the Aflibercept in Polypoidal Choroidal Vasculopathy Study
Tien Yin Wong et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2019)
Long-term Outcome of Intravitreal Aflibercept Treatment for Neovascular Age-Related Macular Degeneration Using a Treat-and-Extend Regimen
Peter G. Traine et al.
OPHTHALMOLOGY RETINA (2019)
The Treat-and-Extend Injection Regimen Versus Alternate Dosing Strategies in Age-related Macular Degeneration: A Systematic Review and Meta-analysis
Mali Okada et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2018)
Optical coherence tomography: A guide to interpretation of common macular diseases
Muna Bhende et al.
INDIAN JOURNAL OF OPHTHALMOLOGY (2018)
Polypoidal Choroidal Vasculopathy Definition, Pathogenesis, Diagnosis, and Management
Chui Ming Gemmy Cheung et al.
OPHTHALMOLOGY (2018)
Treat-and-Extend versus Monthly Regimen in Neovascular Age-Related Macular Degeneration Results with Ranibizumab from the TREND Study
Rufino Silva et al.
OPHTHALMOLOGY (2018)
Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study A Randomized Clinical Trial
Won Ki Lee et al.
JAMA OPHTHALMOLOGY (2018)
Extended Duration Vascular Endothelial Growth Factor Inhibition in the Eye: Failures, Successes, and Future Possibilities
Michael W. Stewart
PHARMACEUTICS (2018)
Age-related macular degeneration
Paul Mitchell et al.
LANCET (2018)
Treat-and-extend therapy using intravitreal aflibercept for neovascular age-related macular degeneration: 2-year real-world practice data from Slovenia
Polona Jaki Mekjavic et al.
BMC OPHTHALMOLOGY (2018)
Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration: Evidence from a Clinical Setting
Maria Eleftheriadou et al.
OPHTHALMOLOGY AND THERAPY (2018)
Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
Winfried Amoaku et al.
CLINICAL OPHTHALMOLOGY (2018)
Treat and Extend versus Pro Re Nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 Month study
Katja Hatz et al.
ACTA OPHTHALMOLOGICA (2017)
One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy
Mio Hosokawa et al.
JAPANESE JOURNAL OF OPHTHALMOLOGY (2017)
Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy
Masahiro Morimoto et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2017)
Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases
Paolo Lanzetta et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2017)
Real-Life Experience with Aflibercept and Ranibizumab in the Treatment of Newly Diagnosed Neovascular Age-Related Macular Degeneration over 24 Months
Justus G. Garweg et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2017)
Comparison of Strategies of Treatment with Ranibizumab in Newly-Diagnosed Cases of Neovascular Age-Related Macular Degeneration
Justus G. Garweg et al.
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (2017)
Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update
Praveen J. Patel et al.
CLINICAL OPHTHALMOLOGY (2017)
A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom
Robert L. Johnston et al.
ADVANCES IN THERAPY (2017)
Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times
Sascha Fauser et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2016)
Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol Two-Year Results
Karina Berg et al.
OPHTHALMOLOGY (2016)
Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration
Frank G. Holz et al.
OPHTHALMOLOGY (2016)
Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials
John W. Kitchens et al.
OPHTHALMOLOGY (2016)
METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Leah N. Kim et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2016)
The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study
Jennifer J. Arnold et al.
BMC OPHTHALMOLOGY (2016)
Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol
Karina Berg et al.
OPHTHALMOLOGY (2015)
Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study
Yuichiro Ogura et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2015)
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
Wan Ling Wong et al.
LANCET GLOBAL HEALTH (2014)
Intraocular Pharmacokinetics of Ranibizumab Following a Single Intravitreal Injection in Humans
Tim U. Krohne et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2012)
Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
Nicholas Papadopoulos et al.
ANGIOGENESIS (2012)
Age-related macular degeneration
Laurence S. Lim et al.
LANCET (2012)
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
Daniel F. Martin et al.
OPHTHALMOLOGY (2012)
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2012)
Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: Same or different disease?
Augustinus Laude et al.
PROGRESS IN RETINAL AND EYE RESEARCH (2010)
Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans
Tim U. Krohne et al.
AMERICAN JOURNAL OF OPHTHALMOLOGY (2008)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
David M. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
分享论文
